Nippon Chemiphar Valuation
Is 4539 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4539 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4539 (¥1511) is trading above our estimate of fair value (¥1255.02)
Significantly Below Fair Value: 4539 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4539?
Key metric: As 4539 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 4539's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | JP¥31.54b |
| Market Cap | JP¥5.45b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 10.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 4539's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.1x | ||
4889 Renascience | 26.9x | n/a | JP¥3.8b |
4579 RaQualia Pharma | 3.6x | 9.6% | JP¥10.0b |
4890 Tsubota Laboratory | 10.1x | n/a | JP¥11.3b |
4582 SymBio Pharmaceuticals | 3.8x | n/a | JP¥11.7b |
4539 Nippon Chemiphar | 0.2x | n/a | JP¥5.5b |
Price-To-Sales vs Peers: 4539 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (11.1x).
Price to Sales Ratio vs Industry
How does 4539's PS Ratio compare vs other companies in the JP Pharmaceuticals Industry?
| 3 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 1.9x | 4.6% | |
4539 Nippon Chemiphar | 0.2x | n/a | US$35.21m |
4541 Nichi-Iko Pharmaceutical | 0.1x | n/a | US$185.57m |
8095 Astena Holdings | 0.4x | n/a | US$127.91m |
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 1.9x | 11.7% | |
4539 Nippon Chemiphar | 0.2x | n/a | US$35.21m |
Price-To-Sales vs Industry: 4539 is good value based on its Price-To-Sales Ratio (0.2x) compared to the JP Pharmaceuticals industry average (1.9x).
Price to Sales Ratio vs Fair Ratio
What is 4539's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4539's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Tsumura
JP¥368.9b
Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.
4540
JP¥4,858.00
7D
1.2%
1Y
76.3%
Shionogi
JP¥1.8t
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
4507
JP¥2,094.50
7D
-2.1%
1Y
-10.9%
ASKA Pharmaceutical HoldingsLtd
JP¥57.7b
Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.
4886
JP¥2,036.00
7D
-2.2%
1Y
13.1%